IDEXX Laboratories Stock Trails S&P 500 in Recent Months

Got story updates? Submit your updates here. ›

IDEXX Laboratories, a leading provider of veterinary diagnostics and software solutions, has seen its stock price decline 25.5% from its 52-week high, underperforming the broader S&P 500 index over the past three and six months. The company reported strong Q4 2025 results, but its stock slipped 4.6% on the news as its gross margin fell short of analyst expectations. Despite the recent underperformance, IDEXX's stock is still up 41.2% over the past 52 weeks, outpacing the S&P 500's 20.1% gain.

Why it matters

IDEXX Laboratories is a large-cap stock and a market leader in the growing veterinary diagnostics industry. Its performance is closely watched by investors as an indicator of broader trends in the animal health sector. The company's recent stock price decline, despite strong financial results, highlights the challenges it faces in maintaining investor confidence amidst macroeconomic headwinds.

The details

IDEXX Laboratories, valued at $45.7 billion, is a leading provider of diagnostic instruments, test kits, software, and laboratory services for veterinary practices, farmers, and laboratories. The company's solutions are used in more than 175 countries, giving it a strong global presence. In Q4 2025, IDEXX reported revenue of $1.1 billion and adjusted earnings of $3.08 per share, both exceeding analyst estimates. However, the company's gross margin of 60.3% fell short of the 61% consensus forecast, causing the stock to slip 4.6% on the news.

• IDEXX Laboratories' stock price has fallen 25.5% from its 52-week high of $769.98.
• Over the past three months, IDEXX's stock has declined 18.5%, trailing the S&P 500's 2.9% fall.
• Over the past six months, IDEXX's stock is down 10.5%, compared to the S&P 500's marginal return.
• However, over the past 52 weeks, IDEXX's stock has rallied 41.2%, outpacing the S&P 500's 20.1% uptick.